نتایج جستجو برای: dlbcl lymphoma

تعداد نتایج: 102737  

2011
Masayuki Shiseki Akihiro Masuda Norimichi Watanabe Masami Fujii Tomofumi Kimura Kentaro Yoshinaga Naoki Mori Masanao Teramura Toshiko Motoji

Waldenström's macroglobulinemia (WM)/ lymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell neoplasm. In rare cases of WM/LPL, diffuse large B-cell lymphoma (DLBCL) develops as a result of histologic transformation. In this report, we present a case of DLBCL developing in a patient with WM/LPL. Combination chemotherapy for DLBCL was effective and complete remission was eventually achiev...

Journal: :Canadian journal of health technologies 2022


 CADTH recommends that Minjuvi, in combination with lenalidomide, not be reimbursed by public drug plans for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) otherwise specified, including DLBCL arising from low grade lymphoma, who are eligible autologous stem cell transplant (ASCT).
 The clinical evidence reviewed was strong enough to show whether ...

Journal: :Blood 2012
Karen E Deffenbacher Javeed Iqbal Warren Sanger Yulei Shen Cynthia Lachel Zhongfeng Liu Yanyan Liu Megan S Lim Sherrie L Perkins Kai Fu Lynette Smith James Lynch Louis M Staudt Lisa M Rimsza Elaine Jaffe Andreas Rosenwald German K Ott Jan Delabie Elias Campo Randy D Gascoyne Mitchell S Cairo Dennis D Weisenburger Timothy C Greiner Thomas G Gross Wing C Chan

Burkitt lymphoma (BL) predominates in pediatric patients, whereas diffuse large B-cell lymphoma (DLBCL) is uncommon. In contrast to adults, BL and DLBCL are treated similarly in children and both entities have superior outcomes in children compared with adults. Gene expression profiling (GEP) and miRNA expression profiling clearly differentiated pediatric DLBCL from BL, forming distinct cluster...

2012
Jae-Yong Kwak

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy. Nonetheless, relapse is detected after treatment with rituximab, cyc...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2017
Jun Tang Darin Salloum Brandon Carney Christian Brand Susanne Kossatz Ahmad Sadique Jason S Lewis Wolfgang A Weber Hans-Guido Wendel Thomas Reiner

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. DLBCL exhibits highly aggressive and systemic progression into multiple tissues in patients, particularly in lymph nodes. Whole-body 18F-fluodeoxyglucose positron emission tomography ([18F]FDG-PET) imaging has an essential role in diagnosing DLBCL in the clinic; however, [18F]FDG-PET often faces difficulty in different...

2012
L Di Lisio M Sánchez-Beato G Gómez-López M E Rodríguez S Montes-Moreno M Mollejo J Menárguez M A Martínez F J Alves D G Pisano M A Piris N Martínez

Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the potential relevance of microRNA (miRNA) expression in a large series that included all major B-cell non-Hodgkin lymphoma (NHL) types. The data generated were also used to identify miRNAs differentially expressed in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) samples. A series ...

Journal: :Hematological oncology 2015
Leticia Quintanilla-Martinez

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), representing around 30% to 40% of all newly diagnosed lymphomas [1]. DLBCL is clinically, morphologically and biologically a heterogeneous disease reflected in the highly variable clinical course. The 2008 World Health Organization (WHO) classification of lymphoid malignancies recognizes within the g...

2011
Julie Gonin Frédérique Larousserie Christian Bastard Jean-Michel Picquenot Jérôme Couturier Isabelle Radford-Weiss Céline Dietrich Nicole Brousse Marie-Cécile Vacher-Lavenu Odile Devergne

The distinction between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), two types of mature aggressive B-cell lymphomas that require distinct treatments, can be difficult because of forms showing features intermediate between DLBCL and BL (here called BL/DLBCL). They can be discriminated by the presence of c-myc translocations characteristic of BL. However, these are not exclus...

2011
Vanessa J. Craig Sergio B. Cogliatti Jochen Imig Christoph Renner Stefan Neuenschwander Hubert Rehrauer Ralph Schlapbach Stephan Dirnhofer Alexander Tzankov Anne Müller

Gastric marginal zone B-cell lymphoma of MALT type (MALT lymphoma) arises in the context of chronic inflammation induced by the bacterial pathogen Helicobacter pylori. Although generally considered an indolent disease, MALT lymphoma may transform to gastric diffuse large B-cell lymphoma (gDLBCL) through mechanisms that remain poorly understood. By comparing microRNA expression profiles of gastr...

Journal: :Cancer research 2016
Brygida Bisikirska Mukesh Bansal Yao Shen Julie Teruya-Feldstein Raju Chaganti Andrea Califano

Follicular lymphoma, the most common indolent subtype of non-Hodgkin lymphoma, is associated with a relatively long overall survival rate ranging from 6 to 10 years from the time of diagnosis. However, in 20% to 60% of follicular lymphoma patients, transformation to aggressive diffuse large B-cell lymphoma (DLBCL) reduces median survival to only 1.2 years. The specific functional and genetic de...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید